A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

NCT01255163 on ClinicalTrials.gov · last registry update 2018-02-22

Stopped early, having planned 57 participants. The sponsor logged completion for 18 November 2016. Primary outcome, as filed: Number of Participants With Incidence of Nausea. exenatide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: National Institute on Aging (NIA)
Sponsor type: Nih
Enrollment: 57
Started: 2010-11-21
Primary completion: 2016-11-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Number of Participants With Incidence of Nausea

Conditions studied

Alzheimer's Disease · Mild Cognitive Impairment

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.